4.5 Article

APOE ε4 status is associated with white matter hyperintensities volume accumulation rate independent of AD diagnosis

期刊

NEUROBIOLOGY OF AGING
卷 53, 期 -, 页码 67-75

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2017.01.014

关键词

White matter hyperintensities; APOE; Alzheimer's disease; Longitudinal

资金

  1. Wolfson Foundation
  2. UCL Faculty of Engineering
  3. EPSRC [EP/H046410/1, EP/J020990/1, EP/K005278]
  4. MRC [MR/J01107X/1]
  5. EU-FP7 project VPH-DARE@IT [FP7-ICT-2011-9-601055]
  6. NIHR Biomedical Research Unit (Dementia) at UCL
  7. National Institute for Health Research University College London Hospitals Biomedical Research Centre (NIHR BRC UCLH/UCL High Impact Initiative) [BW.mn.BRC10269]
  8. EPSRC
  9. NIA
  10. Alzheimer's Research UK
  11. Brain Research Trust
  12. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  13. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  14. National Institute on Aging
  15. National Institute of Biomedical Imaging and Bioengineering
  16. AbbVie
  17. Alzheimer's Association
  18. Alzheimer's Drug Discovery Foundation
  19. Araclon Biotech
  20. BioClinica, Inc
  21. Biogen
  22. Bristol-Myers Squibb Company
  23. CereSpir, Inc
  24. Eisai Inc
  25. Elan Pharmaceuticals, Inc
  26. Eli Lilly and Company
  27. EuroImmun
  28. F. Hoffmann-La Roche Ltd
  29. Genentech, Inc
  30. Fujirebio
  31. GE Healthcare
  32. IXICO Ltd.
  33. Janssen Alzheimer Immunotherapy Research and Development, LLC
  34. Johnson and Johnson Pharmaceutical Research and Development LLC
  35. Lumosity
  36. Lundbeck
  37. Merck and Co, Inc
  38. Meso Scale Diagnostics, LLC
  39. NeuroRx Research
  40. Neurotrack Technologies
  41. Novartis Pharmaceuticals Corporation
  42. Pfizer Inc
  43. Piramal Imaging
  44. Servier
  45. Takeda Pharmaceutical Company
  46. Transition Therapeutics
  47. Canadian Institutes of Health Research
  48. EPSRC [EP/J020990/1, EP/H046410/1] Funding Source: UKRI
  49. MRC [MR/J01107X/1, MR/M009106/1] Funding Source: UKRI
  50. Alzheimers Research UK [ARUK-SRF2016A-2, ARUK-SRF2013-5] Funding Source: researchfish
  51. Engineering and Physical Sciences Research Council [EP/H046410/1, EP/J020990/1] Funding Source: researchfish
  52. Medical Research Council [MR/M009106/1, MR/J01107X/1] Funding Source: researchfish
  53. National Institute for Health Research [NF-SI-0513-10134] Funding Source: researchfish

向作者/读者索取更多资源

To assess the relationship between carriage of APOE epsilon 4 allele and evolution of white matter hyperintensities (WMHs) volume, we longitudinally studied 339 subjects from the Alzheimer's Disease Neuroimaging Initiative cohort with diagnoses ranging from normal controls to probable Alzheimer's disease (AD). A purpose-built longitudinal automatic method was used to segment WMH using constraints derived from an atlas-based model selection applied to a time-averaged image. Linear mixed models were used to evaluate the differences in rate of change across diagnosis and genetic groups. After adjustment for covariates (age, sex, and total intracranial volume), homozygous APOE epsilon 4 epsilon 4 subjects had a significantly higher rate of WMH accumulation (22.5% per year 95% CI [14.4, 31.2] for a standardized population having typical values of covariates) compared with the heterozygous (epsilon 4 epsilon 3) subjects (10.0% per year [6.7, 13.4]) and homozygous e3e3 (6.6% per year [4.1, 9.3]) subjects. Rates of accumulation increased with diagnostic severity; controls accumulated 5.8% per year 95% CI: [2.2, 9.6] for the standardized population, early mild cognitive impairment 6.6% per year [3.9, 9.4], late mild cognitive impairment 12.5% per year [8.2, 17.0] and AD subjects 14.7% per year [6.0, 24.0]. Following adjustment for APOE status, these differences became nonstatistically significant suggesting that APOE epsilon 4 genotype is the major driver of accumulation of WMH volume rather than diagnosis of AD. (C) 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据